Bahrain
Sanofi eyes approval of COVID-19 vaccine by first half of 2021

(BNA): French drugmaker Sanofi SA said on Tuesday it expects to get approval for the potential COVID-19 vaccine it is developing with Britain’s GlaxoSmithKline Plc by the first half of next year, faster than previously anticipated.
Sanofi, which is hosting a virtual research and development event, and GSK had said in April the vaccine, if successful, would be available in the second half of 2021, Reuters reported.
“We are being guided by our dialogue with regulatory authorities,” Sanofi research chief John Reed told reporters, when asked about the accelerated time frame.
There are currently no vaccines to prevent the coronavirus that has infected more than 9 million people and killed over 469,000 globally, and only a couple of medicines that have demonstrated benefit in hospitalized COVID-19 patients in clinical trials.
Many drugmakers are racing to come up with a safe and effective vaccine that can be produced at large scale.
Moderna Inc, the University of Oxford in collaboration with AstraZeneca Plc, and an alliance of BioNTech and Pfizer Inc grabbed headlines by moving to human trials as early as March.
Sanofi Chief Executive Paul Hudson said the firsts in the race now were not assured of securing victory.
“There are companies moving faster, but let us be brutally clear, speed has three downsides,” he said of competition.
“They are using existing work, in many cases done for SARS; it is likely not to be as efficacious; and there is no guarantee on supply in large volumes,” Hudson said.
The probability of success for Sanofi is “higher than anybody else,” the CEO said.
The comments echoed those of GSK, whose chief medical officer for vaccines told Reuters on Friday the company was aiming at quality before speed.
Sanofi, whose Pasteur vaccines division has a long established reputation, notably in flu, is currently working on two vaccine projects.
Clinical trials of the vaccine developed with GSK, described as a recombinant vaccine because of the use of GSK’s boosting adjuvant, are to start in September. Trials of the mRNA vaccine candidate should begin around the end of the year, the company said.
Sanofi said it had capacity to produce up to 1 billion doses a year of its recombinant vaccine, and that it would be able to supply up to 360 million doses of its mRNA vaccine annually.
In April, Sanofi said it had manufacturing capacity for 600 million doses for its recombinant vaccine, with the ambition to double production by mid-2021.
The company also said it would expand its collaboration with Translate Bio on developing vaccines, in a deal which will give the U.S. group $425 million in upfront payments.
-
Banking & Finance2 months ago
National Finance Reinforces Position as Partner for Growth, Offers a Comprehensive Product Suite to Support Customer Ambitions
-
OER Magazines1 month ago
OER, July 25
-
Alamaliktistaad Magazines1 month ago
Al-Iktisaad, July 25
-
Education2 months ago
Russia offers diverse tourism and education opportunities: Sofia Malyavina
-
Digital2 months ago
Russia’s Digital Frontier: An Inside Look with Alexey Goreslavsky of IRI
-
News1 month ago
OpenAI Strengthens ChatGPT’s Mental Health Safeguards Ahead of GPT-5 Launch
-
Banking & Finance2 months ago
Sohar International Partners as Main Sponsor for Refill 3, a Culinary and Cultural Festival Driving Tourism in Khareef Dhofar
-
Energy2 months ago
Oman Investment Authority launches the Sultanate’s First Energy Transition Fund